GSK secures expanded approval for Jemperli from FDA: A major advancement in endometrial cancer treatment
In a landmark decision, the US Food and Drug Administration (FDA) has extended its approval of Jemperli (dostarlimab) to include all adult patients with primary ... Read More
GSK announces significant survival results for Jemperli in endometrial cancer trial
In a significant development for patients with primary advanced or recurrent endometrial cancer, GSK plc (LSE/NYSE: GSK) has disclosed promising outcomes for Jemperli (dostarlimab-gxly) from ... Read More
GSK secures full Jemperli FDA approval for endometrial cancer treatment
Biopharma company GSK has secured the full approval of the US Food and Drug Administration (FDA) for its Jemperli (dostarlimab-gxly) drug for recurrent or advanced ... Read More